Do you want to read an article? Please log in or register.
Mepolizumab alters gene regulatory networks of nasal airway type-2 and epithelial inflammation in urban children with asthma
Asthma
Related content
Further Publications
Down Syndrome Alters Type-III IFN and Pro-Inflammatory Airway Epithelial Responses to RSV Infection
Am J Respir Cell Mol Biol
Chorvinsky E, Bhattacharya S, Bera BS, Welham A, Ismat K, Lawlor CM, Preciado D, Gomez JL, Morizono H, Pillai DK, Gutierrez MJ, Jaiswal JK, Nino G
doi: 10.1165/rcmb.2025-0068OC
COMMENTED
Asthma
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Castro M, Papi A, Porsbjerg C, Lugogo NL, Brightling CE, González-Barcala FJ, Bourdin A, Ostrovskyy M, Staevska M, Chou PC, Duca L, Pereira AM, Fogarty C, Nadama R, Zhang M, Rodrigues A, Soler X, Sacks HJ, Deniz Y, Rowe PJ, de Prado Gómez L, Jacob-Nara JA
doi: 10.1016/S2213-2600(24)00362-X
RECOMMENDED
Asthma
The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Rimkunas A, Januskevicius A, Vasyle E, Palacionyte J, Kalinauskaite-Zukauske V, Miliauskas S, Malakauskas K
doi: 10.2147/JAA.S509001
COMMENTED
COPD
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB
doi: 10.1016/S2213-2600(24)00409-0
Further Publications
Impact of the COVID-19 Pandemic on Healthcare Utilization Rates and Obesity in Urban Minority Children With High Asthma Disease Burden: A Retrospective Cohort Study
Pediatr Pulmonol
Sun Y, Treyster Z, Rastogi D, Conrad LA
doi: 10.1002/ppul.71175
RECOMMENDED
COPD
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Christenson SA, Hanania NA, Bhatt SP, Bafadhel M, Rabe KF, Vogelmeier CF, Papi A, Singh D, Laws E, Dakin P, Bansal A, Lu X, Bauer D, Maloney J, Robinson LB, Abdulai RM
doi: 10.1016/S2213-2600(25)00044-X
Asthma
Small Airways Disease as a Novel Target for Mepolizumab in Asthma-The SASAM Prospective Real-Life Study
J Clin Med
Bonini M, Boccabella C, Cefaloni F, De Corso E, Donfrancesco F, Schiavi E, Richeldi L
doi: 10.3390/jcm14092928
COPD
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores
Respir Med
Vogelmeier CF, Rabe KF, Bhatt SP, Hanania NA, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Maloney J, Dakin P, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM
doi: 10.1016/j.rmed.2025.108015
Asthma
Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)
Allergy Asthma Immunol Res
Park SY, Lee D, Kim JH, Lee Y, Ban GY, Sim DW, Kwon JW, Kim SR, Song WJ, Park HW, Chang YS, Koh YI, Lee BJ, Park HS, Cho YS, Kim SH
doi: 10.4168/aair.2025.17.3.384